The global Central Precocious Puberty Market is estimated to be valued at US$ 1.722.2 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:Central precocious puberty refers to the early onset of sexual maturation before the normal age of 8 years in girls and 9 years in boys. The condition is commonly treated using GnRH analogs that stop premature activation of the hypothalamic-pituitary-gonadal axis and block sex hormone production to slow pubertal progression.
Market key trends:
One of the key trends in the central precocious puberty market is the development of long-acting GnRH analog injections. Traditionally, patients require frequent injections ranging from once a month to once every 3 months for treatment. However, new drug formulations such as leuprorelin and triptorelin are being developed as 6-month or 12-month long-acting injections. These new formulations offer improved patient convenience and compliance by reducing injection frequency.
Segment Analysis
The global central precocious puberty market is segmented on the basis of drug type into gonadotropin-releasing hormone agonists and others. The gonadotropin-releasing hormone agonists segment currently dominates the market due to the wider availability and acceptance of drugs such as Lupron in this category for the treatment of central precocious puberty. These agonists act by suppressing the pituitary gland and decreasing the levels of estrogen or testosterone in the body, thus delaying puberty.
Key Takeaways
The global central precocious puberty market is expected to witness high growth, exhibiting CAGR of 7.9% over the forecast period, due to increasing prevalence of central precocious puberty.
Regional analysis
North America is expected to dominate the global central precocious puberty market over the forecast period owing to higher awareness regarding the condition and availability of advanced treatment options in the region. Asia Pacific is anticipated to exhibit the fastest growth due to rising healthcare expenditure and growing medical tourism in countries such as India.
Key players
Key players operating in the central precocious puberty market are Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited. Teva Pharmaceutical Industries Ltd. currently dominates the market due to its widely available gonadotropin-releasing hormone agonist drug called Lupron.
The global central precocious puberty market is segmented on the basis of drug type into gonadotropin-releasing hormone agonists and others. The gonadotropin-releasing hormone agonists segment currently dominates the market due to the wider availability and acceptance of drugs such as Lupron in this category for the treatment of central precocious puberty. These agonists act by suppressing the pituitary gland and decreasing the levels of estrogen or testosterone in the body, thus delaying puberty.
Key Takeaways
The global central precocious puberty market is expected to witness high growth, exhibiting CAGR of 7.9% over the forecast period, due to increasing prevalence of central precocious puberty.
Regional analysis
North America is expected to dominate the global central precocious puberty market over the forecast period owing to higher awareness regarding the condition and availability of advanced treatment options in the region. Asia Pacific is anticipated to exhibit the fastest growth due to rising healthcare expenditure and growing medical tourism in countries such as India.
Key players
Key players operating in the central precocious puberty market are Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited. Teva Pharmaceutical Industries Ltd. currently dominates the market due to its widely available gonadotropin-releasing hormone agonist drug called Lupron.
No comments:
Post a Comment